Richard S E Keefe

List of Publications by Year
in descending order

279	34,381	5574 82	3732 179
papers	citations	h-index	g-index

291	291	291	19085
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, 2005, 353, 1209-1223.	27.0	5,335
2	The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. American Journal of Psychiatry, 2008, 165, 203-213.	7.2	1,863
3	The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research, 2004, 68, 283-297.	2.0	1,209
4	Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2657-64.	7.1	1,173
5	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Archives of General Psychiatry, 2007, 64, 633.	12.3	928
6	Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry, 2004, 56, 301-307.	1.3	818
7	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. American Journal of Psychiatry, 2006, 163, 600-610.	7.2	760
8	Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis. Archives of General Psychiatry, 2005, 62, 361.	12.3	712
9	Schizophrenia Is a Cognitive Illness. JAMA Psychiatry, 2013, 70, 1107.	11.0	649
10	The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis. Schizophrenia Bulletin, 1999, 25, 201-222.	4.3	636
11	The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization. American Journal of Psychiatry, 2008, 165, 214-220.	7.2	593
12	Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment. American Journal of Psychiatry, 2001, 158, 176-184.	7.2	581
13	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. American Journal of Psychiatry, 2006, 163, 600.	7.2	513
14	Static and Dynamic Cognitive Deficits in Childhood Preceding Adult Schizophrenia: A 30-Year Study. American Journal of Psychiatry, 2010, 167, 160-169.	7.2	483
15	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. Neuropsychopharmacology, 2006, 31, 2033-2046.	5.4	408
16	Barriers to Employment for People With Schizophrenia. American Journal of Psychiatry, 2006, 163, 411-417.	7.2	390
17	Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium<subtitle>Relationship to Family History and Conversion to Psychosis</subtitle><alt-title>Neuropsychology of Prodrome to Psychosis</alt-title>. Archives of General Psychiatry, 2010, 67, 578.	12.3	390
18	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. PLoS Genetics, 2009, 5, e1000373.	3.5	383

#	Article	IF	Citations
19	Cognitive Impairment in Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 11-37.	1.8	335
20	How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment?. Schizophrenia Bulletin, 2007, 33, 912-920.	4.3	332
21	The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity. American Journal of Psychiatry, 2006, 163, 426-432.	7.2	325
22	Neuropsychological Impairments in Schizophrenia and Psychotic Bipolar Disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. American Journal of Psychiatry, 2013, 170, 1275-1284.	7.2	320
23	Defining a cognitive function decrement in schizophrenia. Biological Psychiatry, 2005, 57, 688-691.	1.3	312
24	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. American Journal of Psychiatry, 2006, 163, 611-622.	7.2	312
25	Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol. American Journal of Psychiatry, 2004, 161, 985-995.	7.2	289
26	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research, 2008, 102, 108-115.	2.0	281
27	A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology, 2015, 40, 2025-2037.	5.4	258
28	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal of Psychiatry, 2006, 163, 2080-2089.	7.2	247
29	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. American Journal of Psychiatry, 2007, 164, 428-436.	7.2	246
30	A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophrenia Research, 2006, 88, 26-35.	2.0	236
31	Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. American Journal of Psychiatry, 2007, 164, 1061-1071.	7.2	234
32	Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. American Journal of Psychiatry, 2011, 168, 831-839.	7.2	232
33	Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry, 2008, 193, 279-288.	2.8	228
34	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. American Journal of Psychiatry, 2006, 163, 611.	7.2	221
35	Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version. Psychiatry and Clinical Neurosciences, 2007, 61, 602-609.	1.8	206
36	Functional Co-Primary Measures for Clinical Trials in Schizophrenia: Results From the MATRICS Psychometric and Standardization Study. American Journal of Psychiatry, 2008, 165, 221-228.	7.2	204

#	Article	IF	Citations
37	The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study. Schizophrenia Research, 2011, 126, 124-131.	2.0	204
38	Neuropsychological Decline in Schizophrenia From the Premorbid to the Postonset Period: Evidence From a Population-Representative Longitudinal Study. American Journal of Psychiatry, 2014, 171, 91-101.	7.2	201
39	The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research, 2005, 80, 9-18.	2.0	189
40	A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. The Lancet Digital Health, 2020, 2, e168-e178.	12.3	186
41	Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research, 2011, 125, 161-168.	2.0	183
42	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. American Journal of Psychiatry, 2008, 165, 978-987.	7.2	182
43	Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology, 2009, 34, 1885-1903.	5.4	168
44	A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research, 1995, 17, 25-33.	2.0	165
45	Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. Schizophrenia Research, 2002, 57, 51-67.	2.0	155
46	A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. Biological Psychiatry, 2011, 69, 442-449.	1.3	155
47	Altered Striatal Functional Connectivity in Subjects With an At-Risk Mental State for Psychosis. Schizophrenia Bulletin, 2014, 40, 904-913.	4.3	152
48	Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users. American Journal of Psychiatry, 2005, 162, 2352-2359.	7.2	149
49	Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophrenia Research, 2005, 80, 33-43.	2.0	146
50	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. American Journal of Psychiatry, 2007, 164, 415-427.	7.2	138
51	Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Neuropsychopharmacology, 2008, 33, 1217-1228.	5.4	135
52	Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research, 1994, 53, 1-12.	3.3	133
53	Science and Recovery in Schizophrenia. Psychiatric Services, 2008, 59, 487-496.	2.0	133
54	Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. World Psychiatry, 2008, 7, 22-28.	10.4	132

#	Article	IF	Citations
55	The Relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to Functional Capacity and Real-world Functional Outcome. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 260-269.	1.3	129
56	Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research, 2009, 107, 1-12.	2.0	129
57	A randomized proof-of-mechanism trial applying the â€˜fast-failâ€™ approach to evaluating Î¹-opioid antagonism as a treatment for anhedonia. Nature Medicine, 2020, 26, 760-768.	30.7	129
58	Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research, 1995, 59, 127-136.	3.3	125
59	The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?. Schizophrenia Bulletin, 2011, 37, 1209-1217.	4.3	121
60	Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an Î±7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacology, 2015, 40, 3053-3060.	5.4	120
61	Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?. Schizophrenia Bulletin, 2013, 39, 417-435.	4.3	117
62	Insight in first-episode psychosis. Psychological Medicine, 2006, 36, 1385-1393.	4.5	115
63	One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia Research, 2006, 81, 1-15.	2.0	114
64	Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis. Biological Psychiatry, 2006, 59, 97-105.	1.3	113
65	Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatric Services, 2006, 57, 1094-1101.	2.0	112
66	Lamotrigine as Add-On Therapy in Schizophrenia. Journal of Clinical Psychopharmacology, 2007, 27, 582-589.	1.4	112
67	Neurocognitive Assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial: Development, Methodology, and Rationale. Schizophrenia Bulletin, 2003, 29, 45-55.	4.3	111
68	Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. Psychiatric Services, 2008, 59, 500-506.	2.0	110
69	Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research, 2012, 136, 25-31.	2.0	110
70	The Longitudinal Course of Cognitive Impairment in Schizophrenia. Journal of Clinical Psychiatry, 2014, 75, 8-13.	2.2	110
71	Eye Tracking, Attention, and Schizotypal Symptoms in Nonpsychotic Relatives of Patients With Schizophrenia. Archives of General Psychiatry, 1997, 54, 169.	12.3	109
72	Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies. Neuropsychopharmacology, 2010, 35, 1053-1062.	5.4	109

#	Article	IF	Citations
73	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. Schizophrenia Bulletin, 2013, 39, 564-574.	4.3	109
74	Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. Neuropsychopharmacology, 2011, 36, 616-626.	5.4	103
75	Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: Negative symptoms. Psychiatry Research, 1992, 44, 153-165.	3.3	99
76	Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging. American Journal of Psychiatry, 2013, 170, 1451-1459.	7.2	95
77	Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis â€" Findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophrenia Research, 2015, 164, 8-14.	2.0	94
78	A Brain-Computer Interface Based Cognitive Training System for Healthy Elderly: A Randomized Control Pilot Study for Usability and Preliminary Efficacy. PLoS ONE, 2013, 8, e79419.	2.5	92
79	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. European Journal of Human Genetics, 2009, 17, 946-957.	2.8	89
80	Cognitive Effects of Pharmacotherapy for Major Depressive Disorder. Journal of Clinical Psychiatry, 2014, 75, 864-876.	2.2	88
81	Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research, 2011, 127, 188-194.	2.0	86
82	The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research, 2009, 115, 17-23.	2.0	85
83	Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial. Journal of Clinical Psychiatry, 2012, 73, 1016-1022.	2.2	85
84	The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. Schizophrenia Bulletin, 2017, 43, 57-63.	4.3	84
85	Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. Journal of Clinical Psychopharmacology, 2015, 35, 374-381.	1.4	81
86	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research, 2005, 80, 1-8.	2.0	80
87	NCAM1 and Neurocognition in Schizophrenia. Biological Psychiatry, 2007, 61, 902-910.	1.3	80
88	Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research, 2008, 105, 1-9.	2.0	79
89	Elevated Antisaccade Error Rate as an Intermediate Phenotype for Psychosis Across Diagnostic Categories. Schizophrenia Bulletin, 2014, 40, 1011-1021.	4.3	78
90	Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophrenia Bulletin, 2016, 42, 335-343.	4.3	78

#	Article	IF	Citations
91	A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians. Schizophrenia Bulletin, 2011, 37, 538-545.	4.3	77
92	The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research, 2010, 121, 24-31.	2.0	76
93	Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. Schizophrenia Bulletin, 2011, 37, 1057-1065.	4.3	76
94	Visuospatial working memory in schizotypal personality disorder patients. Schizophrenia Research, 2000, 41, 447-455.	2.0	75
95	Measuring outcome priorities and preferences in people with schizophrenia. British Journal of Psychiatry, 2005, 187, 529-536.	2.8	74
96	Cognition as an outcome measure in schizophrenia. British Journal of Psychiatry, 2007, 191, s46-s51.	2.8	72
97	A Randomized, Placebo-Controlled Study Investigating the Nicotinic Î±7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1568-1577.	5.4	71
98	Cognitive burden of anticholinergic medications in psychotic disorders. Schizophrenia Research, 2017, 190, 129-135.	2.0	71
99	Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophrenia Research, 1997, 26, 9-14.	2.0	70
100	Methodological Issues in Negative Symptom Trials. Schizophrenia Bulletin, 2011, 37, 250-254.	4.3	67
101	Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: Formal thought disorder. Psychiatry Research, 1992, 44, 141-151.	3.3	62
102	Validation of the tablet-administered Brief Assessment of Cognition (BAC App). Schizophrenia Research, 2017, 181, 100-106.	2.0	62
103	Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 1388-1398.	5.4	61
104	Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. Innovations in Clinical Neuroscience, 2017, 14, 30-40.	0.1	61
105	Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophrenia Research, 1995, 17, 123-129.	2.0	60
106	Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 462-471.	1.3	60
107	Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia. Neuropsychopharmacology, 2013, 38, 1245-1252.	5.4	60
108	A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research, 2015, 164, 136-142.	2.0	59

#	Article	IF	Citations
109	Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry, 2004, 65, 361-72.	2.2	59
110	Behavioral response inhibition in psychotic disorders: Diagnostic specificity, familiality and relation to generalized cognitive deficit. Schizophrenia Research, 2014, 159, 491-498.	2.0	58
111	Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry,the, 2021, 8, 191-201.	7.4	58
112	Attentional markers of vulnerability to schizophrenia: Performance of medicated and unmedicated patients and normals. Psychiatry Research, 1990, 33, 179-188.	3.3	57
113	Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 2009, 9, 44.	2.6	57
114	Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. Journal of Clinical Psychiatry, 2011, 72, 295-303.	2.2	57
115	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research, 2011, 132, 177-182.	2.0	56
116	Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology, 2014, 231, 3647-3662.	3.1	54
117	Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. JAMA Psychiatry, 2018, 75, 929.	11.0	54
118	Validation of a Computerized test of Functional Capacity. Schizophrenia Research, 2016, 175, 90-96.	2.0	53
119	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews Drug Discovery, 2019, 18, 82-84.	46.4	52
120	D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophrenia Research, 1996, 20, 29-32.	2.0	51
121	Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study: Table 1.. Schizophrenia Bulletin, 2015, 41, 1285-1293.	4.3	51
122	The Cognitive Assessment Interview (CAI): Reliability and Validity of a Brief Interview-Based Measure of Cognition. Schizophrenia Bulletin, 2013, 39, 583-591.	4.3	50
123	Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Translational Psychiatry, 2018, 8, 78.	4.8	49
124	Cortical and subcortical white matter abnormalities in adults with remitted firstâ€episode mania revealed by Tractâ€Based Spatial Statistics. Bipolar Disorders, 2010, 12, 383-389.	1.9	48
125	Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia Research, 2013, 150, 542-546.	2.0	47
126	Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: A diffusion tensor imaging study. Journal of Psychiatric Research, 2015, 62, 115-122.	3.1	47

#	Article	IF	Citations
127	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
128	The Longitudinal Youth at Risk Study (LYRIKS) â€" An Asian UHR perspective. Schizophrenia Research, 2013, 151, 279-283.	2.0	46
129	Information-processing markers of vulnerability to schizophrenia: performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Research, 1996, 60, 49-56.	3.3	45
130	Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.. Psychological Assessment, 2011, 23, 245-261.	1.5	45
131	Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Current Medical Research and Opinion, 2010, 26, 2403-2410.	1.9	44
132	Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance. Schizophrenia Research: Cognition, 2014, 1, e21-e26.	1.3	44
133	Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. European Neuropsychopharmacology, 2015, 25, 176-184.	0.7	44
134	Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innovations in Clinical Neuroscience, 2013, 10, 4S-19S.	0.1	44
135	Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophrenia Research, 1991, 4, 71-79.	2.0	43
136	The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls. Journal of Affective Disorders, 2014, 166, 86-92.	4.1	43
137	Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia. Journal of Clinical Psychiatry, 2010, 71, 1475-1481.	2.2	43
138	Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society, 2008, 14, 209-21.	1.8	41
139	Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment. CNS Spectrums, 1997, 2, 41-55.	1.2	40
140	Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. Schizophrenia Research, 2009, 107, 275-285.	2.0	40
141	Observable Social Cognition â€" A Rating Scale: an interview-based assessment for schizophrenia. Cognitive Neuropsychiatry, 2015, 20, 198-221.	1.3	40
142	Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. Innovations in Clinical Neuroscience, 2017, 14, 18-22.	0.1	39
143	Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis. Schizophrenia Bulletin, 2010, 36, 43-47.	4.3	38
144	The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. Journal of Clinical Psychopharmacology, 2017, 37, 651-656.	1.4	37

#	Article	IF	Citations
145	Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale. Biological Psychiatry, 1996, 40, 755-760.	1.3	36
146	Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bulletin, 2015, 42, sbv111.	4.3	34
147	Placebo Response and Practice Effects in Schizophrenia Cognition Trials. JAMA Psychiatry, 2017, 74, 807.	11.0	34
148	BL-1020, a New Î³-Aminobutyric Acidâ€“Enhanced Antipsychotic. Journal of Clinical Psychiatry, 2012, 73, e1168-e1174.	2.2	34
149	Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia. Schizophrenia Research, 1997, 26, 139-146.	2.0	33
150	Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophrenia Research, 2017, 190, 172-179.	2.0	33
151	Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Research, 1991, 38, 285-292.	3.3	32
152	Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia Research, 2013, 151, 107-112.	2.0	32
153	Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. European Psychiatry, 2007, 22, 365-370.	0.2	31
154	A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research, 2012, 138, 35-38.	2.0	30
155	Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biological Psychiatry, 1996, 39, 902-905.	1.3	29
156	Memory-Prediction Errors and Their Consequences in Schizophrenia. Neuropsychology Review, 2009, 19, 336-352.	4.9	29
157	Research with Spanish-Speaking Populations in the United States: Lost in the Translation A Commentary and a Plea. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 555-564.	1.3	28
158	White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: A diffusion tensor imaging study. Psychiatry Research - Neuroimaging, 2009, 172, 121-127.	1.8	28
159	Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. Schizophrenia Research, 2011, 130, 47-52.	2.0	28
160	Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A). Journal of Psychiatric Research, 2015, 60, 81-86.	3.1	28
161	Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. Schizophrenia Bulletin, 2018, 44, 286-296.	4.3	28
162	Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophrenia Bulletin, 2019, 45, 350-359.	4.3	28

#	Article	IF	Citations
163	Technology, society, and mental illness: challenges and opportunities for assessment and treatment. Innovations in Clinical Neuroscience, 2012, 9, 47-50.	0.1	28
164	Formulation of the ageâ€“education index: Measuring age and education effects in neuropsychological performance.. Psychological Assessment, 2013, 25, 61-70.	1.5	27
165	Preserved Working Memory and Altered Brain Activation in Persons at Risk for Psychosis. American Journal of Psychiatry, 2013, 170, 1297-1307.	7.2	27
166	Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders. Biological Psychiatry, 2007, 62, 226-234.	1.3	26
167	Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. Schizophrenia Bulletin, 2017, 43, sbw081.	4.3	26
168	Cognitive deficits in patients with schizophrenia: effects and treatment. Journal of Clinical Psychiatry, 2007, 68 Suppl 14, 8-13.	2.2	26
169	Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. Psychopharmacology, 2003, 169, 383-389.	3.1	25
170	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1298-1300.	1.7	25
171	The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research, 2013, 206, 195-199.	3.3	25
172	Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. European Archives of Psychiatry and Neurological Sciences, 1989, 239, 39-42.	0.9	24
173	Sensory acuity and reasoning in delusional disorder. Comprehensive Psychiatry, 2002, 43, 175-178.	3.1	24
174	Second-generation antipsychotics: reviewing the costâ€“effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 103-111.	1.4	24
175	Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms. Journal of Clinical Psychiatry, 2018, 79, .	2.2	24
176	Progress in Experimental Personality and Psychopathology Research, vol. 15. American Journal of Psychiatry, 1995, 152, 288-289.	7.2	24
177	Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. Schizophrenia Research, 2006, 85, 106-112.	2.0	23
178	Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. Schizophrenia Research, 2015, 166, 310-315.	2.0	23
179	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. Schizophrenia Research, 2019, 208, 182-189.	2.0	22
180	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processingâ€“Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychiatry, 2016, 77, 799-806.	2.2	22

#	Article	IF	Citations
181	Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks. Schizophrenia Bulletin, 2007, 34, 656-663.	4.3	21
182	Standardizing the use of the Continuous Performance Test in schizophrenia research: A validation study. Schizophrenia Research, 2012, 142, 153-158.	2.0	21
183	Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia. Schizophrenia Research: Cognition, 2018, 12, 11-19.	1.3	21
184	Why are there no approved treatments for cognitive impairment in schizophrenia?. World Psychiatry, 2019, 18, 167-168.	10.4	21
185	Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. Journal of Behavioral Health Services and Research, 2008, 35, 215-225.	1.4	19
186	Schizophrenia is a disorder of higher order hierarchical processing. Medical Hypotheses, 2009, 72, 740-744.	1.5	19
187	Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia. JAMA Psychiatry, 2017, 74, 535.	11.0	19
188	Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. Schizophrenia Research, 2019, 204, 155-161.	2.0	19
189	Differential effects of emotional information on interference task performance across the life span. Frontiers in Aging Neuroscience, 2010, 2, .	3.4	18
190	Comprehensive model of how reality distortion and symptoms occur in schizophrenia: Could impairment in learningâ€dependent predictive perception account for the manifestations of schizophrenia?. Psychiatry and Clinical Neurosciences, 2011, 65, 305-317.	1.8	18
191	Development of a Virtual Reality Assessment of Everyday Living Skills. Journal of Visualized Experiments, 2014, , .	0.3	18
192	The Schizophrenia Cognition Rating Scale: Validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Research, 2010, 178, 33-38.	3.3	17
193	Validation of the <scp>P</scp>ersian version of the Brief Assessment of Cognition in Schizophrenia in patients with schizophrenia and healthy controls. Psychiatry and Clinical Neurosciences, 2014, 68, 160-166.	1.8	17
194	Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. Microbial Biotechnology, 2020, 14, 106-114.	1.7	17
195	Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. Schizophrenia Bulletin, 2021, 47, 712-721.	4.3	17
196	Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology, 2021, 46, 1802-1810.	5.4	17
197	The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research, 2018, 195, 306-317.	2.0	17
198	Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults. American Journal of Psychiatry, 2022, 179, 482-489.	7.2	17

#	Article	IF	Citations
199	Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study. Cerebral Cortex, 2018, 28, 4234-4243.	2.9	16
200	Genetic correlates of insight in schizophrenia. Schizophrenia Research, 2018, 195, 290-297.	2.0	16
201	Testâ€"Retest Reliability of the Dot Test of Visuospatial Working Memory in Patients with Schizophrenia and Controls. Schizophrenia Research, 2000, 45, 169-173.	2.0	15
202	Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. Schizophrenia Bulletin, 2015, 41, 940-950.	4.3	15
203	Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS). Dementia E Neuropsychologia, 2007, 1, 260-265.	0.8	14
204	Failures in Learning-Dependent Predictive Perception as the Key Cognitive Vulnerability to Psychosis in Schizophrenia. Neuropsychopharmacology, 2011, 36, 367-368.	5.4	14
205	Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research, 2013, 146, 217-223.	2.0	14
206	Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample. Archives of Clinical Neuropsychology, 2013, 28, 845-858.	0.5	14
207	Applicability of the MATRICS Consensus Cognitive Battery in Singapore. Clinical Neuropsychologist, 2013, 27, 455-469.	2.3	14
208	Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research, 2014, 218, 39-43.	3.3	13
209	Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. Schizophrenia Research, 2018, 193, 83-90.	2.0	13
210	AKT1 and Neurocognition in Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2007, 41, 169-177.	2.3	12
211	Cognition and Motivation as Treatment Targets in Schizophrenia. JAMA Psychiatry, 2014, 71, 987.	11.0	12
212	Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis. Schizophrenia Research: Cognition, 2016, 6, 1-8.	1.3	12
213	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. Journal of Psychiatric Research, 2021, 133, 38-45.	3.1	12
214	Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.5	12
215	Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies. Schizophrenia Research, 2014, 159, 205-210.	2.0	11
216	Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. Schizophrenia Research, 2018, 201, 85-90.	2.0	11

#	Article	IF	Citations
217	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research, 2021, 228, 29-35.	2.0	11
218	Criminal Justice System Involvement Among People with Schizophrenia. Community Mental Health Journal, 2011, 47, 727-736.	2.0	10
219	Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Research, 2012, 200, 835-842.	3.3	10
220	The Continuous Performance Test, Identical Pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore. Schizophrenia Research, 2014, 156, 233-240.	2.0	10
221	Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. Psychiatry Research, 2019, 277, 58-63.	3.3	10
222	No association of the serotonin transporter polymorphisms 5â€HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1115-1117.	1.7	9
223	How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. Cognitive Neuropsychiatry, 2013, 18, 243-251.	1.3	9
224	TOMMORROW neuropsychological battery: German language validation and normative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 314-323.	3.7	9
225	Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. Schizophrenia Research, 2020, 223, 297-304.	2.0	9
226	Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. Annals of the Academy of Medicine, Singapore, 2009, 38, 414-6.	0.4	9
227	The Singapore flagship programme in translational and clinical research in psychosis. Microbial Biotechnology, 2011, 5, 290-300.	1.7	8
228	Treating cognitive impairment in depression: an unmet need. Lancet Psychiatry,the, 2016, 3, 392-393.	7.4	8
229	Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. Asian Journal of Psychiatry, 2017, 27, 12-15.	2.0	8
230	Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. Patient Preference and Adherence, 2012, 6, 521.	1.8	7
231	Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). Schizophrenia Research, 2019, 210, 30-38.	2.0	7
232	A randomized Phase <scp>II</scp> trial evaluating efficacy, safety, and tolerability of oral <scp>BI</scp> 409306 in attenuated psychosis syndrome: Design and rationale. Microbial Biotechnology, 2021, 15, 1315-1325.	1.7	7
233	Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia. Schizophrenia Research, 2020, 223, 166-172.	2.0	6
234	Verbal memory measurement towards digital perspectives in first-episode psychosis: A review. Schizophrenia Research: Cognition, 2020, 21, 100177.	1.3	6

#	Article	IF	Citations
235	Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. Neuropsychopharmacology, 2021, 46, 844-850.	5.4	6
236	Do Novel Antipsychotics Improve Cognition? A Report of a Meta-Analysis. Psychiatric Annals, 1999, 29, 623-629.	0.1	6
237	Understanding Symbol Coding in Schizophrenia. Biological Psychiatry, 2015, 78, 744-746.	1.3	5
238	Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder. Psychiatry Research, 1997, 73, 33-45.	3.3	4
239	Integrated genetic and genomic approach in the Singapore translational and clinical research in psychosis study: an overview. Microbial Biotechnology, 2011, 5, 91-99.	1.7	4
240	A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia. Schizophrenia Research, 2020, 222, 450-454.	2.0	4
241	Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1917-1925.	2.8	4
242	An abbreviated version of the brief assessment of cognition in schizophrenia (BACS). European Journal of Psychiatry, 2015, 29, 131-134.	1.3	3
243	Methods for Delivering and Evaluating the Efficacy of Cognitive Enhancement. Handbook of Experimental Pharmacology, 2015, 228, 5-25.	1.8	3
244	Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. Schizophrenia Research: Cognition, 2019, 18, 100155.	1.3	3
245	Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110464.	4.8	3
246	Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study. European Psychiatry, 2020, 63, e40.	0.2	3
247	Dr. Lieberman and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 555-a-556.	7.2	2
248	Commentary on O'Halloran et al. Schizophrenia Research, 2009, 107, 327-329.	2.0	2
249	Neurocognition. , 0, , 97-119.		2
250	868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. Biological Psychiatry, 2017, 81, S351.	1.3	2
251	M25. Development and Validation of the Brief Assessment of Validation in Schizophrenia (BAC-App). Schizophrenia Bulletin, 2017, 43, S220-S220.	4.3	2
252	T32. INTACT AUDITORY PERCEPTION IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S215-S215.	4.3	2

#	Article	IF	Citations
253	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research: Cognition, 2020, 19, 100161.	1.3	2
254	Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. Schizophrenia Research, 2021, 236, 54-60.	2.0	2
255	Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?. Psychiatry, 2008, 5, 55-9.	0.3	2
256	symptom correlates of poor eye tracking in patients with schizotypal personality disorder and relatives of schizophrenic probands. Biological Psychiatry, 1989, 25, A102-A103.	1.3	1
257	Dr. Keefe and Colleagues Reply. American Journal of Psychiatry, 2007, 164, 1911-1912.	7.2	1
258	Clues to the Cognitive and Perceptual Origins of Social Isolation and Psychosis in Schizophrenia. American Journal of Psychiatry, 2012, 169, 354-357.	7.2	1
259	P3-255: CULTURAL ADAPTATION OF TRANSLATED NEUROCOGNITIVE ASSESSMENTS IN RUSSIA, SWITZERLAND AND ITALY: PILOT TESTING FOR A PROGRAM TO DELAY THE ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE. , 2014, 10, P725-P726.		1
260	[P4â€“578]: EXPANDING THE BRIEF ASSESSMENT OF COGNITION (BACâ€APP) FOR ASSESSMENT OF COGNITION IN AGING: INITIAL FINDINGS FROM AN ONGOING NORMATIVE STUDY. Alzheimer's and Dementia, 2017, 13, P1574.	0.8	1
261	A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. International Journal of Neuropsychopharmacology, 2018, 21, 442-447.	2.1	1
262	O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS. Schizophrenia Bulletin, 2019, 45, S175-S175.	4.3	1
263	Theta Burst for Cognitive Remediation in Schizophrenia. Journal of ECT, 2020, 36, 72-74.	0.6	1
264	Where do we cut the bell-shaped curve of CIAS?. Schizophrenia Research, 2021, 228, 633-634.	2.0	1
265	Biologic markers for personality disorders: A dimensional approach. Biological Psychiatry, 1989, 25, A140.	1.3	0
266	Using family history screening for linkage studies in schizophrenia. Biological Psychiatry, 1989, 25, A144.	1.3	0
267	The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date. , 0, , 177-191.		0
268	Assessment of cognition in schizophrenia treatment studies. , 0, , 231-246.		0
269	Predicting Schizophrenia. JAMA Psychiatry, 2016, 73, 441.	11.0	0
270	T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION?. Schizophrenia Bulletin, 2018, 44, S196-S197.	4.3	0

#	Article	IF	Citations
271	P1â€050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAYâ€OFâ€ONSET PHASE 3 CLINICAL TRIAL. Alzheimer's and Dementia, 2018, 14, P286.	0.8	0
272	Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 900-902.	1.5	0
273	T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY. Schizophrenia Bulletin, 2018, 44, S159-S159.	4.3	0
274	M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S180-S181.	4.3	0
275	Requisite Skills and the Meaningful Measurement of Cognition. JAMA Psychiatry, 2020, 77, 1103.	11.0	0
276	Schizophrenia: All Pathways to Symptoms Pass Through Cognitive Deficits?. PsycCritiques, 1996, 41, 900-902.	0.0	0
277	Dr Kantrowitz and Colleagues Reply. Journal of Clinical Psychiatry, 2016, 77, e1353-e1353.	2.2	0
278	Missing the sweet spot disengagement in schizophrenia. Psychiatry, 2006, 3, 36-41.	0.3	0
279	Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis. Schizophrenia Research: Cognition, 2022, 27, 100225.	1.3	0